Frédéric Baron

Sep 1, 2024 | onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Myriam Labopin |Sorbonne Paris France

CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Pfizer, Celgene, Abbvie, Novartis, and Sanofi. JV has received speaker honoraria from AbbVie and ExCellThera. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, , , et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: long-term follow up of a phase III study. Am J Hematol. 2020; 95: 749-758.

May 2, 2024 | biorxiv.org | Bianca Silva |Frédéric Baron |Grégory Ehx |Charline Faville

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) is the main therapeutic approach for patients with high-risk acute myeloid leukemia (AML), but the rate of relapse remains high and is associated with poor outcomes. Discovering new approaches to maximize the graft-versus-leukemia (GVL) effects while mitigating graft-versus-host disease (GVHD) should therefore be pursued.

Oct 2, 2023 | onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Arnon Nagler |Jacques-Emmanuel Galimard

CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Celgene, Abbvie, Novartis, Pfizer and Sanofi. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, . Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022; 2022: 23–29. 2, , , , , , et al. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancer. 2020; 12(11): 3334. 3, , , , , , et al.